Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes.

Rizzo, Manfredi; Cosentino, Francesco; Mantzoros, Christos

Rizzo, Manfredi; Cosentino, Francesco; Mantzoros, Christos.

Rizzo M; Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialties (Promise), School of Medicine, University of Palermo, Palermo, Italy.
Cosentino F; Division of Cardiology, Department of Medicine, Karolinska Institute and Karolinska University Hospital, University of Stockholm, Stockholm, Sweden.
Mantzoros C; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Expert Rev Clin Pharmacol ; 15(7): 795-797, 2022 07.

Article in English | MEDLINE | ID: covidwho-2062750

Subject(s)

Biosimilar Pharmaceuticals; Diabetes Mellitus, Type 2; Biosimilar Pharmaceuticals/pharmacology; Biosimilar Pharmaceuticals/therapeutic use; Diabetes Mellitus, Type 2/drug therapy; Drugs, Generic/pharmacology; Drugs, Generic/therapeutic use; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents/pharmacology; Hypoglycemic Agents/therapeutic use; Liraglutide/pharmacology; Liraglutide/therapeutic use

Keywords

Biosimilar; GLP-1; diabetes; generics; liraglutide; treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Biosimilar Pharmaceuticals Type of study: Prognostic study Limits: Humans Language: English Journal: Expert Rev Clin Pharmacol Year: 2022 Document Type: Article Affiliation country: 17512433.2022.2108400

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google